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Introduction and Historical 
Soon after the discovery of radioactivity it was 
shown that radionuclides can be used both for 
diagnostic and therapeutic studies, depending 
on the characteristic radiations emitted by 
them. By 1960’s the radionuclide production 
technology using nuclear reactors was well es-
tablished. In early 1970’s a renaissance of the 
cyclotrons occurred because many of the neu-
tron deficient radionuclides could only be pro-
duced using irradiations with charged particles, 
like protons, deuterons, α-particles, etc. Initially, 
interest was directed towards radioactive gases 
for inhalation studies and other radionuclides 
for scintigraphy. Later, with the advent of emis-
sion tomography, i.e. Single Photon Emission 
Computed Tomography (SPECT) and Positron 
Emission Tomography (PET), the emphasis shift-
ed to 123I and positron emitters [cf. 1–3], and 
tremendous progress ensued. In order to keep 
abreast of the fast developments, a Symposium 
was organized at the Brookhaven National La-
boratory (BNL), USA, in 1976, with the title “Ra-
diopharmaceutical Chemistry”. This became a 
biennial event, with alternate meetings in North 
America and Europe. It included all aspects of 
radionuclide and radiopharmaceutical research. 
About a decade later, however, it was realized 
that for discussion of technical aspects, a sepa-
rate forum would be more appropriate. A group 
of experts therefore convened the first Targetry 
Workshop in Heidelberg in 1985. Thereafter it 
was established as a recurring Workshop, with 
its scope enlargened to include also nuclear and 
radiochemical problems. Today, the major con-
ference on Radiopharmaceutical Sciences and 
the specialist International Workshop on Target-
ry and Target Chemistry are held in alternate 
years. The present Workshop is No. 15 in the 
series and it is being jointly held by the research 
groups in Dresden and Prague, both of which 
have a long tradition of cyclotron production of 
radionuclides. In this talk, some personal remi-
niscences and impressions of the historical de-
velopments in the field over the last 40 years 
will be briefly described.  
 
 
 
Development Steps 
The development of cyclotron radionuclides 
involves work in three major directions [cf. 4,5]: 
a) Nuclear data studies. 
b) High-current targetry. 
c) Chemical separations and quality  
assurance.  
A brief review of the developments and 
achievements in each direction is presented.  
 
Nuclear data studies 
An accurate knowledge of nuclear data is a pre-
requisite for developing a production route. 
Data measurements related to cyclotron radio-
nuclides are much more demanding than in the 
case of reactor produced radionuclides [cf. 6]. 
Extensive excitation function measurements 
using highly enriched target material and high-
resolution γ- or X-ray spectrometry are manda-
tory. Special attention needs to be paid to de-
termination of charged particle flux and energy 
degradation in the target constituents. To date 
both gaseous and solid targets have been used 
for nuclear reaction cross section measure-
ments. The techniques have reached a certain 
degree of perfection and, in recent years, the 
uncertainties in properly measured cross sec-
tions have been considerably reduced. A few 
typical examples of recent nuclear data meas-
urements will be shown [cf. 7]. Some attention 
has also been paid to standardization, evalua-
tion and validation of data for commonly used 
radionuclides through the use of nuclear model 
calculations, statistical fitting procedures and 
integral yield measurement [cf. 8,9]. The status 
of data will be discussed.  
 
High-current targetry 
Development of high-current targets has been 
one of the major challenges in large scale pro-
duction of cyclotron radionuclides. Often a nu-
clear reaction with a relatively low yield may be 
chosen for production, if targetry is easier. Since 
often enriched material is irradiated, economic 
considerations play an important role in target 
design and construction [cf. 10].  
 
All three forms of materials, viz. solid, liquid and 
gas, have been finding application. Whereas in 
irradiation of gaseous and liquid targets a per-
pendicular collimated beam is used and the 
target is operated under high pressure to keep 
the change in the target density within con-
trolled limits, in case of solid targets a broad-
ened and wobbled slanting beam is often em-
ployed. An efficient heat transfer from the tar-
get is mandatory. In general, for the production 
of commonly used short-lived PET radionuclides 
(11C, 13N, 15O, 18F) at dedicated small-sized cyclo-
trons, gaseous or liquid targets are used. A 
spherical water target has proven to be very 
effective for large scale production of 18F, the 
most important PET-radionuclide. Also in the 
production of the SPECT-radionuclide 123I at a 
medium-sized cyclotron, high-class gas target 
technology is utilized. In most of the other cases, 
e.g. metallic SPECT, PET and therapeutic radio-
nuclides, both at small and medium-sized cyclo-
trons, solid targets are used. As a result of con-
stant developments [for review, cf. 4, 11], so-
phisticated target systems are now available. 
 
Chemical separations 
For separation of desired radionuclides from 
cyclotron irradiated targets, both dry and wet 
chemical processing methods have been at-
tempted [for review, cf. 4,5]. The dry distillation 
process may be optimized to obtain the purified 
radionuclide in a very small volume of the sol-
vent. A variation of the process, termed as 
thermochromatography, leads only to a removal 
of the desired activity from the strong matrix, 
which is generally followed by a more refined 
separation method. The wet chemical pro-
cessing, on the other hand, may involve all types 
of separation techniques, such as ion-
chromatography, solvent extraction, electrolysis, 
etc. Many of the techniques have been very well 
developed. Examples relevant to the production 
of a few novel radionuclides like 124I, 64Cu, 55Co, 
etc. will be given. Some special precautions 
needed to assure good specific activity will be 
discussed.  
 
Conclusions and Perspectives 
As a result of vast research and development 
work in all the areas discussed above, dispersed 
over a span of several decades, the radionuclide 
production technology at a cyclotron has now 
reached a level of high sophistication. The impe-
tus has also come through the development of 
dedicated high-powered cyclotrons and high-
resolution imaging devices. In the case of short-
lived positron emitters, for example, full produc-
tion units, consisting of a cyclotron, set of suita-
ble targets and apparatus for chemical separa-
tion and synthesis can be commercially ob-
tained. Yet it is vital that research and develop-
ment work continues. In particular, if the supply 
chain of some established radionuclides is jeop-
ardized, alternative routes of production need to 
be developed. 
The present emphasis with regard to cyclotron 
production of medical radionuclides is on longer 
lived positron emitters and highly-ionizing low-
range emitting therapeutic radionuclides. Some 
other emerging areas of interest [cf. 12] include 
a combination of PET and Magnetic Resonance 
Imaging (MRI) as well as of radioactivity and 
nanotechnology. The future perspectives of 
some radionuclides, potentially useful in those 
areas of applications, will be considered. The 
increasing significance of intermediate energy, 
multi-particle cyclotrons in production of some 
radionuclides will be outlined.  
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